---
schema_version: "secwatch.filing_event.v1"
accession: "0001001233-25-000023"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:17:07.298248+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sangamo Q3 net loss $34.9M, revenue $0.6M; advancing Fabry BLA and pain trial enrollment

## Summary
- Q3 2025 consolidated net loss $34.9M ($0.11/sh) vs net income $10.7M ($0.04/sh) in prior year.
- Revenue of $0.6M down from $49.4M, mainly due to absence of Genentech collaboration revenue.
- Cash and equivalents $29.6M; with Pfizer $6M license fee and ATM proceeds, runway into Q1 2026.
- FDA reiterated eGFR slope endpoint for isaralgagene civaparvovec accelerated approval; BLA submission expected as early as Q1 2026.
- First two clinical sites activated for Phase 1/2 ST-503 chronic neuropathic pain study; first patient dosing expected in coming months.

## SEC filing metadata
- accession: 0001001233-25-000023
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000100123325000023/0001001233-25-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000100123325000023/sgmo-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001001233-25-000023
- JSON: https://secwatch.observer/filing/0001001233-25-000023.json
- Plain text: https://secwatch.observer/filing/0001001233-25-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.